Advanced search

News (307)

Transcript : Pfizer Inc., Q1 2024 Earnings Call, May 01, 2024	01/05
Notice of Annual General Meeting in Vimian Group AB (publ)	19/04	AQ
Transcript : Pfizer Inc. Presents at Leerink Partners Global Biopharma Conference 2024, Mar-12-2024 08:00 AM	12/03
Pfizer : Leerink Partners Global Biopharma Conference 2024 Transcript	12/03	PU
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference	05/03	BU
Transcript : Pfizer Inc., Q4 2023 Earnings Call, Jan 30, 2024	30/01
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity	04/12	AQ
Pfizer nixes more study of twice-daily obesity pill treatment that made many patients nauseous	01/12	AQ
Pfizer drops plan to study twice-daily obesity pill in late-stage studies	01/12	RE
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity	01/12	BU
Transcript : Pfizer Inc., Q3 2023 Earnings Call, Oct 31, 2023	31/23/31
Transcript : Pfizer Inc. Presents at Citi 18th Annual BioPharma Conference, Sep-07-2023 10:30 AM	07/23/07
Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences	30/23/30	BU
Transcript : Pfizer Inc., Q2 2023 Earnings Call, Aug 01, 2023	01/23/01
Pfizer Reports Second-Quarter 2023 Results	01/23/01	BU
Pfizer Inc. Announces Restructuring of its Research and Development Organization with Oncology as a Stand-Alone Unit	28/23/28	CI
Pfizer Inc. Announces Executive Changes	28/23/28	CI
Pfizer Announces Executive Leadership to Advance Oncology Research and Development Strategy	27/23/27	BU
Pfizer, Flagship Pioneering to invest $100 mln in drug discovery	18/23/18	RE
Flagship Pioneering and Pfizer Partner to Accelerate Development of Innovative Medicines Targeting Unmet Needs	18/23/18	PR
Transcript : Pfizer Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-13-2023 08:00 AM	13/23/13
Press release from the Annual General Meeting in Vimian Group AB (publ) on 2 June 2023	02/23/02	AQ
Notice of Annual General Meeting in Vimian Group AB (publ)	03/23/03	AQ
Transcript : Pfizer Inc., Q1 2023 Earnings Call, May 02, 2023	02/23/02
AGILENT TECHNOLOGIES, INC. : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	18/23/18	AQ
Transcript : Pfizer Inc., Seagen Inc. - M&A Call	13/23/13
Transcript : Pfizer Inc., Q4 2022 Earnings Call, Jan 31, 2023	31/23/31
Transcript : Pfizer Inc. - Special Call	12/22/12
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases	01/22/01	GL
Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases	01/22/01	AQ
Transcript : Pfizer Inc., Q3 2022 Earnings Call, Nov 01, 2022	01/22/01
Alexandria Real Estate Equities, Inc./Alexandria Venture Investments Executive Chairman and Founder Joel S. Marcus Appointed to the Prix Galien USA's Esteemed Awards Jury to Recognize Groundbreaking Medical Innovations in Life Science	27/22/27	PR
Pfizer - CytoReason Announces Expanded Collaboration Deal with Pfizer to Deliver AI for Drug Discovery and Development	21/22/21	AQ
Transcript : Pfizer Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-12-2022 01:40 PM	12/22/12
Transcript : Pfizer Inc. Presents at Citi's 17th Annual BioPharma Conference, Sep-07-2022 10:30 AM	07/22/07
Pfizer Invites Public to View and Listen to Two Webcasts of Pfizer Discussions at Healthcare Conferences	01/22/01	BU
Transcript : Pfizer Inc. - Special Call	24/22/24
Transcript : Pfizer Inc. Presents at Handelsbanken Life Science Innovation Day 2022, Aug-24-2022 10:30 AM	24/22/24
Pfizer : Press Relase(opens in new window)	24/22/24	PU
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference	19/22/19	BU
Transcript : Pfizer Inc., Q2 2022 Earnings Call, Jul 28, 2022	28/22/28
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus	28/22/28	GL
Roivant and Pfizer Unveil Priovant Therapeutics and Ongoing Registrational Studies for Oral Brepocitinib in Dermatomyositis and Lupus	28/22/28	BU
Transcript : Pfizer Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 08:40 AM	15/22/15
Pfizer : Transcript Updated(opens in new window)	10/22/10	PU

1234NextSee all

Companies (2)

ANNEXIN PHARMACEUTICALS AB 10 M $

Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV h ...

ANNEXIN PHARMACEUTICALS AB (PUBL) 10 M $

Insiders

Mikael Dolsten

Mikael Dolsten holds the position of Chief Scientific Officer & Research President at Pfizer Inc. Dr. Dolsten is also on the board of New York Academy of Sciences, Karyopharm Therapeutics, Inc. and PhRMA Foundation and Member of Royal Swedish Academy of Engineering Sciences and Member of Government-University-Industry Research Roundtable. In the past he occupied the position of Principal at OrbiMed Advisors LLC and Partner at OrbiMed Advisors Private Equity (a subsidiary of OrbiMed Advisors LLC), President for Wyeth Research, EVP, Global Head-Pharma Research & Discovery at Boehringer Ingelheim Pharmaceuticals, Inc., Senior Vice President for Wyeth Corp. and Member-Benefits, Law & Regulatory Committee at Wyeth Pharmaceuticals LLC. Dr. Dolsten received a doctorate from the University of Lund.

No results for this search